Sarepta therapeutics announces fourth quarter and full-year 2023 financial results and recent corporate developments

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2023. “we are pleased to report another strong quarter and year of performance serving the patient community. with our three approved pmo therapies, exondys 51, vyondys 53 and amondys 45, and supported by the successful launch of our gene therapy, elevidys, sarepta's net product revenue grew.
SRPT Ratings Summary
SRPT Quant Ranking